Effect of Porus One on Reducing Uremic Toxins in Cats with Naturally Occurring CKD
Uremic toxins are substances that build up in the body due to decreased removal by the kidney. They are increased in patients with CKD and correlate to severity of disease. Indoxyl sulfate is one of the most studied uremic toxins and comes from byproducts of protein metabolism in the gut. It is thought to contribute to progression of CKD including increasing fibrosis and inflammation in the kidney as well as affecting other body systems such as the heart, bones, and muscle. Porus One (Renaltec) is a new patented pure carbon product that acts as an adsorbent of the protein byproduct so that it cannot be absorbed and converted into indoxyl sulfate. Instead, it is excreted in the feces. Porus One has been shown to decrease indoxyl sulfate in normal geriatric cats. The purpose of this study is to assess its effect in cats with CKD.
Click Here for Informed Consent Form
Efficacy of Potassium Citrate as a Treatment for Metabolic Acidosis in Cats with Chronic Kidney Disease
Hypokalemia (low potassium levels in the blood) and metabolic acidosis (high amount of acid in the body) are two very important consequences of chronic kidney disease (CKD), leading to worsened clinical signs at home. Metabolic acidosis plays a role in progression of CKD and its treatment has been shown to improve long-term outcome in human patients with CKD. However, the treatment of metabolic acidosis in cats with CKD remains a challenge, with very few safe and effective options available. Potassium citrate is a medication normally used to supplement potassium that also has alkalinizing properties which allow it to correct metabolic acidosis with minimal side effects. However, there is very little information available in veterinary medicine regarding the efficacy of potassium citrate as a treatment for metabolic acidosis. Therefore, the purpose of this study to evaluate whether potassium citrate can effectively correct metabolic acidosis in cats with chronic kidney disease in comparison to a non-alkalinizing form of potassium supplementation.
Click Here for Informed Consent Form
Effect of Transdermal Mirtazapine on Quality of Life in Cats with Chronic Kidney Disease
Poor appetite is common in cats with chronic kidney disease (CKD) and can result in weight loss and poor body condition. Poor appetite is as an important aspect of quality of life and is recognized to cause significant emotional distress to caregivers. Transdermal mirtazapine (Mirataz®) is frequently used as an appetite support in CKD cats suffering from inappetence.The purpose of this study is to assess the effect of appetite stimulation on quality of life in cats with CKD. A better understanding of the effect of management of inappetence in CKD on quality of life will improve our ability to help our CKD cats.
Click Here for Informed Consent Form
Coming Soon!
- Kidney Protection Blend Diet for Cats with CKD